IL3 and graft versus host disease: To determine whether ND630-treated human Tregs have increased in vivo potency, a xenogeneic GVHD model was used, in which sublethally irradiated NOD/Scid/IL-2γc–/–/IL-3/GM/SF mice were given peripheral blood mononuclear cells (PBMCs) to induce acute xenogeneic GVHD (66, 67).